Empagliflozin: all 403 studies that test it
Page 1 of 5. Open to participants first (103), then studies with results posted, then the rest; newest registration first within each.
- EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)Not yet recruitingNCT07883512Phase 2
- Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid ArthritisNot yet recruitingNCT07864688Phase 2
- A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyRecruitingNCT07845630Phase 1
- The GranStone TrialNot yet recruitingNCT07828002Phase 2/3
- Cardioprotective Effect of Empagliflozin in Breast Cancer PatientsNot yet recruitingNCT07815808Phase 3
- Neurovascular Effects of EmpagliflozinNot yet recruitingNCT07799441Phase 4
- The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes MellitusRecruitingNCT07771010Phase 4
- Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseNot yet recruitingNCT07756294Phase 2
- Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI PatientsNot yet recruitingNCT07749014Phase 2
- the Clinical Outcome of Empagliflozin in Pediatric Heart Failure PatientsRecruitingNCT07692256Phase 2
- Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled TrialNot yet recruitingNCT07678151Not applicable
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
- PRECISE Phenotyping to Guide Therapies for Coronary Microvascular DysfunctionNot yet recruitingNCT07533747Phase 3
- Empagliflozin Adjunctive Therapy in Bipolar DepressionNot yet recruitingNCT07472920Not applicable
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationNCT07452913Phase 4
- Glycemic Variability of Combination Therapies in T2DMRecruitingNCT07442006Phase 4
- Add-on Diuretics in Acute Decompensated Heart FailureRecruitingNCT07372040Phase 2
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus PatientsNot yet recruitingNCT07365358Phase 4
- Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based TherapyRecruitingNCT07336797Phase 2
- A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinRecruitingNCT07331389Phase 1
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With CirrhosisRecruitingNCT07322237Phase 4
- Effect of Empagliflozin on InflammationRecruitingNCT07292909Phase 4
- SGLT2i Therapy in Islet Transplantation (SIT)RecruitingNCT07228195Phase 4
- SGLT2 Inhibitors in Adult Primary Nephrotic SyndromeRecruitingNCT07214818Phase 2/3
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver DiseaseNot yet recruitingNCT07180745Phase 4
- Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, EmpagliflozinRecruitingNCT07175051Phase 2
- Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNot yet recruitingNCT07155694Phase 4
- Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada SyndromeNot yet recruitingNCT07146880Phase 2
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminRecruitingNCT07093476Phase 3
- Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 InhibitorEnrolling by invitationNCT07065357Phase 3
- Vascular Effects of SGLT2i in Non-diabetic CKDNot yet recruitingNCT07060417Phase 2
- SGLT2i in Kidney StonesRecruitingNCT07055282Early Phase 1
- SGLT2i, Pioglitazone, and Ketone Production in T2DRecruitingNCT07053319Phase 1
- SGLT2i, Ketoacidosis, Volume Contraction, and InsulinopeniaRecruitingNCT07053306Phase 1
- SGLT2i, Hepatic Glucose Production, and SNSRecruitingNCT07053293Early Phase 1
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart FailureRecruitingNCT07038356Phase 3
- Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionRecruitingNCT06992440Phase 2
- Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 DiabetesRecruitingNCT06989723Phase 4
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory FailureRecruitingNCT06955260Phase 3
- A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesRecruitingNCT06894784Phase 3
- Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingNCT06862739Phase 4
- The EMPA-FIT StudyRecruitingNCT06846411Phase 4
- Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With ObesityRecruitingNCT06745063Phase 2
- Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes MellitusRecruitingNCT06729996Phase 2
- EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined SourceRecruitingNCT06715449Phase 2/3
- Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type IIRecruitingNCT06706791Phase 4
- SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) TrialRecruitingNCT06674109Phase 4
- Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionRecruitingNCT06653738Phase 3
- Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of AgeNot yet recruitingNCT06643442Phase 2
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordRecruitingNCT06642272Phase 4
- The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with MethotrexateNot yet recruitingNCT06641128Phase 4
- Randomized Trial of SGLT2i in Heart Transplant RecipientsRecruitingNCT06625073Phase 4
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 DiabetesRecruitingNCT06613854Phase 4
- To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy AdultsRecruitingNCT06578676Phase 1
- Feasibility Trial for a Right Ventricular Failure Platform TrialRecruitingNCT06570473Phase 2
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRecruitingNCT06528405Phase 2
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart FailureRecruitingNCT06507657Early Phase 1
- Empagliflozin Reversal of Arterial StiffnEss in AgingRecruitingNCT06506422Phase 2/3
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsRecruitingNCT06483074Phase 2
- Efficacy of SGLT2 Inhibitors in Adults With SepsisRecruitingNCT06473844Not applicable
- Prevention of Progression of Prediabetes, Obesity and CV RiskRecruitingNCT06446531Phase 1
- Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSeaseRecruitingNCT06430684Early Phase 1
- Use of SGLT2i in noHCM With HFpEFRecruitingNCT06401343Phase 4
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver DiseaseRecruitingNCT06355310Phase 2
- Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai VolunteersNot yet recruitingNCT06337409Phase 1
- A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting ConditionsNot yet recruitingNCT06308679Phase 1
- EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal DiseaseRecruitingNCT06249945Phase 4
- Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal DiseaseRecruitingNCT06249932Phase 4
- Ketones, SGLT2, HFrEFRecruitingNCT06229678Early Phase 1
- Treatment of Patients With Diabetic Kidney DiseaseNot yet recruitingNCT06187493Not applicable
- Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKDRecruitingNCT06110130Phase 4
- Cardioprotective Empagliflozin for Cancer Patients Receiving DoxorubicinNot yet recruitingNCT06103279Phase 2/3
- Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes MellitusNot yet recruitingNCT06098625Not applicable
- Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes MellitusRecruitingNCT06095492Not applicable
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With HypertensionRecruitingNCT06055452Phase 4
- Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionRecruitingNCT06046612Phase 4
- The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1RecruitingNCT06030843Phase 2/3
- Empagliflozin Treatment in Kidney Transplant RecipientsRecruitingNCT06013865Phase 4
- Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose RationaleNot yet recruitingNCT06012266Phase 2
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionRecruitingNCT05972564Phase 1/2
- SGLTi, Hepatic Glucose Production and KetogenesisRecruitingNCT05960656Phase 1
- Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLDNot yet recruitingNCT05942963Phase 4
- Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatmentRecruitingNCT05905965Phase 3
- Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.RecruitingNCT05879276Phase 3
- Safety and Efficacy of Empagliflozin in HemodialysisRecruitingNCT05786443Phase 2
- Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureRecruitingNCT05776043Phase 3
- Empagliflozin in Patients With Cirrhosis and AscitesRecruitingNCT05726032Phase 2
- meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsisRecruitingNCT05715814Phase 3
- Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsRecruitingNCT05669742Phase 3
- Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative ColitisRecruitingNCT05610956Early Phase 1
- Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection FractionEnrolling by invitationNCT05600387Phase 4
- EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection FractionEnrolling by invitationNCT05584319Phase 4
- Empagliflozin for New On-set Heart Failure Study Regardless of Ejection FractionRecruitingNCT05556044Phase 3
- Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesRecruitingNCT05501483Not applicable
- Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart FailureRecruitingNCT05392764Phase 3
- Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE StudyRecruitingNCT05164263Phase 4
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNot yet recruitingNCT05140694Phase 4
- SGLT2i and KNO3 in HFpEF - The SAK HFpEF TrialRecruitingNCT05138575Phase 2
- SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research PlanRecruitingNCT05057806Early Phase 1
- Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialRecruitingNCT04535960Phase 2